Literature DB >> 22820968

Genetic counseling, activism and 'genotype-first' diagnosis of developmental disorders.

Daniel Navon1.   

Abstract

This paper presents a sociological examination of the role of genetic counselors as advocates, not only for patients and their families, but also for genetic conditions themselves. In becoming activists for new disorders, genetic counselors are helping to create new categories that will shape expectations and treatment regimens for both existing patients and those who are yet to be diagnosed. By virtue of their expertise and their position at the intersection of several key professions and constituencies, genetic counselors are likely to play a central role in the way the genetic testing technologies, and especially 'genotype-first' diagnosis, impacts the way we understand and categorize developmental difference. I outline some of the promises and dangers that this kind of activism holds for people with developmental disabilities, and particularly the challenge presented by systemic ascertainment bias in the face of genotype-phenotype uncertainty. I argue that new testing techniques like microarray analysis that do not need to be targeted on the basis of clinical presentation throw these challenges into sharp relief, and that the genetic counseling community should consider how to marry advocacy for new genetic conditions with an emphasis on the indeterminate developmental potential of every child.

Entities:  

Mesh:

Year:  2012        PMID: 22820968     DOI: 10.1007/s10897-012-9515-9

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  32 in total

1.  Genomic designation: how genetics can delineate new, phenotypically diffuse medical categories.

Authors:  Daniel Navon
Journal:  Soc Stud Sci       Date:  2011-04       Impact factor: 3.885

2.  A new definition of Genetic Counseling: National Society of Genetic Counselors' Task Force report.

Authors:  Robert Resta; Barbara Bowles Biesecker; Robin L Bennett; Sandra Blum; Susan Estabrooks Hahn; Michelle N Strecker; Janet L Williams
Journal:  J Genet Couns       Date:  2006-04       Impact factor: 2.537

3.  Cytogenetic technology--genotype and phenotype.

Authors:  David H Ledbetter
Journal:  N Engl J Med       Date:  2008-09-10       Impact factor: 91.245

4.  22q13 deletion syndrome.

Authors:  M C Phelan; R C Rogers; R A Saul; G A Stapleton; K Sweet; H McDermid; S R Shaw; J Claytor; J Willis; D P Kelly
Journal:  Am J Med Genet       Date:  2001-06-15

Review 5.  Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies.

Authors:  David T Miller; Margaret P Adam; Swaroop Aradhya; Leslie G Biesecker; Arthur R Brothman; Nigel P Carter; Deanna M Church; John A Crolla; Evan E Eichler; Charles J Epstein; W Andrew Faucett; Lars Feuk; Jan M Friedman; Ada Hamosh; Laird Jackson; Erin B Kaminsky; Klaas Kok; Ian D Krantz; Robert M Kuhn; Charles Lee; James M Ostell; Carla Rosenberg; Stephen W Scherer; Nancy B Spinner; Dimitri J Stavropoulos; James H Tepperberg; Erik C Thorland; Joris R Vermeesch; Darrel J Waggoner; Michael S Watson; Christa Lese Martin; David H Ledbetter
Journal:  Am J Hum Genet       Date:  2010-05-14       Impact factor: 11.025

6.  Characterization of Potocki-Lupski syndrome (dup(17)(p11.2p11.2)) and delineation of a dosage-sensitive critical interval that can convey an autism phenotype.

Authors:  Lorraine Potocki; Weimin Bi; Diane Treadwell-Deering; Claudia M B Carvalho; Anna Eifert; Ellen M Friedman; Daniel Glaze; Kevin Krull; Jennifer A Lee; Richard Alan Lewis; Roberto Mendoza-Londono; Patricia Robbins-Furman; Chad Shaw; Xin Shi; George Weissenberger; Marjorie Withers; Svetlana A Yatsenko; Elaine H Zackai; Pawel Stankiewicz; James R Lupski
Journal:  Am J Hum Genet       Date:  2007-02-26       Impact factor: 11.025

7.  A place for genetic uncertainty: parents valuing an unknown in the meaning of disease.

Authors:  Ian Whitmarsh; Arlene M Davis; Debra Skinner; Donald B Bailey
Journal:  Soc Sci Med       Date:  2007-06-11       Impact factor: 4.634

8.  Genetic counseling for the 22q11.2 deletion.

Authors:  Donna M McDonald-McGinn; Elaine H Zackai
Journal:  Dev Disabil Res Rev       Date:  2008

9.  Deletions and microdeletions of 22q11.2 in velo-cardio-facial syndrome.

Authors:  D A Driscoll; N B Spinner; M L Budarf; D M McDonald-McGinn; E H Zackai; R B Goldberg; R J Shprintzen; H M Saal; J Zonana; M C Jones
Journal:  Am J Med Genet       Date:  1992-09-15

10.  Phenotype of the 22q11.2 deletion in individuals identified through an affected relative: cast a wide FISHing net!

Authors:  D M McDonald-McGinn; M K Tonnesen; A Laufer-Cahana; B Finucane; D A Driscoll; B S Emanuel; E H Zackai
Journal:  Genet Med       Date:  2001 Jan-Feb       Impact factor: 8.822

View more
  3 in total

1.  Emerging Genetic Counselor Roles within the Biotechnology and Pharmaceutical Industries: as Industry Interest Grows in Rare Genetic Disorders, How are Genetic Counselors Joining the Discussion?

Authors:  Tessa Field; Stephanie Jo Brewster; Meghan Towne; MaryAnn W Campion
Journal:  J Genet Couns       Date:  2016-03-28       Impact factor: 2.537

2.  A qualitative study of healthcare providers' perspectives on the implications of genome-wide testing in pediatric clinical practice.

Authors:  Marian Reiff; Rebecca Mueller; Surabhi Mulchandani; Nancy B Spinner; Reed E Pyeritz; Barbara A Bernhardt
Journal:  J Genet Couns       Date:  2013-09-14       Impact factor: 2.537

3.  Understanding the Psychosocial Effects of WES Test Results on Parents of Children with Rare Diseases.

Authors:  Lotte Krabbenborg; L E L M Vissers; J Schieving; T Kleefstra; E J Kamsteeg; J A Veltman; M A Willemsen; S Van der Burg
Journal:  J Genet Couns       Date:  2016-04-20       Impact factor: 2.537

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.